Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 199
Scaling Up Treatment for the Global AIDS Pandemic: Challenges and Opportunities Appendix A Information Gathering Workshop Agenda Committee on Examining the Probable Consequences of Alternative Patterns of Widespread Antiretroviral Drug Use in Resource-Constrained Settings Tuesday, January 27, 2004 Room 100, Keck Building 500 5th Street, NW Washington, DC 2001 8:00-8:20 Welcome, Introduction of Committee, and Statement of Charge Dr. James Curran and Dr. Haile Debas Committee Cochairs The Opportunity 8:20-8:45 The Challenge of HIV/AIDS in 2004 and the WHO 3 × 5 Program Dr. Jim Kim Advisor to the Director-General World Health Organization Geneva, Switzerland

OCR for page 199
Scaling Up Treatment for the Global AIDS Pandemic: Challenges and Opportunities 8:45-9:10 The Global Funds’ Lessons Learned Regarding ARV Drug Scale-up in Resource-Constrained Settings Dr. Bernhard Schwartlander Director Strategic Information and Measurement Global Fund to Fight AIDS, TB, and Malaria Geneva, Switzerland 9:10-9:35 The U.S. Emergency Plan for Antiretroviral Scale-up: The Latest Programmatic Developments Dr. Joe O’Neil Deputy Coordinator Office of the Global AIDS Coordinator Department of State Washington, DC 9:35-9:55 General Discussion 9:55-10:15 BREAK Antecedents 10:15-10:40 Durability of ARV Therapy: U.S. Experience and Its Implications for Resource-Constrained Settings Dr. Robert Redfield Cofounder and Director of Clinical Care and Research Division, Institute of Human Virology University of Maryland Baltimore, MD 10:40-11:05 A U.S. Clinical Perspective on the Implications of ARV Resistance for Resource-Constrained Settings Dr. Steven Deeks Associate Clinical Professor of Clinical Medicine University of California, San Francisco San Francisco, CA 11:05-11:30 Lessons Learned from the Scale-up of ARV Treatment in Brazil Dr. Mauro Schechter Professor of Infectious Diseases Universidade Federal do Rio de Janeiro, Brazil

OCR for page 199
Scaling Up Treatment for the Global AIDS Pandemic: Challenges and Opportunities 11:30-11:55 Lessons Learned from the Use of ARVs in Very Low-Resource Settings: The Haiti Experience Dr. Daniel Fitzgerald Groupe Haitien d’Étude du Sarcome de Kaposi et des infections Opportunistes (GHESKIO) Port-au-Prince, Haiti, and Division of International Medicine and Infectious Diseases Cornell University Medical College New York, NY 11:55-12:20 MSF Perspectives on ARV Administration: Experiences from 20 countries and 10,000 Patients Ms. Rachel Cohen U.S. Director, Campaign for Access to Essential Medicines Médecins sans Frontières New York, NY 12:20-12:50 General Discussion 12:50-1:50 LUNCH Clinical Principles for ARV Scale-up Programs 1:50-2:15 The 2003 WHO Guidelines for ARV Use: Perspectives from a User Dr. John Idoko Professor Jos University Teaching Hospital Jos, Nigeria 2:15-2:40 MTCT-Plus Initiative: Perspectives from a Multicountry Comprehensive HIV Care and Treatment Program Dr. Wafaa El-Sadr Professor Mailman School of Public Health Columbia University and Harlem Hospital New York, NY

OCR for page 199
Scaling Up Treatment for the Global AIDS Pandemic: Challenges and Opportunities 2:40-3:05 The Role of the Laboratory in Managing ARV Care in a Country with Highly Limited Resources   Dr. Brooks Jackson   Baxley Professor and Director of Pathology   Johns Hopkins University School of Medicine   Baltimore, MD 3:05-3:30 The Social and Behavioral Dimensions of Adherence: Implications for Patient Education   Dr. Carla Makhlouf Obermeyer   Scientist   Department of HIV/AIDS   World Health Organization   Geneva, Switzerland 3:30-3:50 General Discussion 3:50-4:10 BREAK 4:10-4:35 Preventing Mother-to-Child Transmission: Issues of Therapy and Resistance   Dr. Lynne Mofenson   Pediatric, Adolescent and Maternal AIDS Branch   Center for Research for Mothers and Children   National Institute of Child Health and Human Development   National Institutes of Health   Bethesda, MD 4:35-5:00 Pediatric Considerations for ARV Programs in Resource-Constrained Settings   Dr. Mark Kline   Chief, Retrovirology Clinic   Professor of Pediatrics   Director, Baylor International Pediatric AIDS Initiative   Baylor College of Medicine/Texas Children’s Hospital   Houston, TX

OCR for page 199
Scaling Up Treatment for the Global AIDS Pandemic: Challenges and Opportunities 5:00-5:25 The Integration of Counseling, Prevention, and ARV Programs   Dr. Sam Dooley   Division of HIV/AIDS Prevention   Centers for Disease Control and Prevention   Atlanta, GA 5:25-6:00 Wrap-up Comments and Discussion Wednesday, January 28, 2004 Management Principles for Scale-up of ARV Programs 8:00-8:05 Opening Comments   Dr. James Curran and Dr. Haile Debas   Committee Cochairs 8:05-8:30 Principles of Design and Scale-up for National Clinical Care Programs and Applications to the WHO 3 × 5 Targets   Dr. M. Rashad Massoud   Vice President and Director   Quality and Performance Institute   University Research Co., LLC   Bethesda, MD 8:30-8:55 An Overview of Health Care Manpower, Health Care Infrastructure, and Economics in Select Resource-Poor Countries   Mr. Mead Over   Lead Economist   Development Research Group   World Bank   Washington, DC 8:55-9:20 The Role of Community Mobilization in the Scale-up of ARV programs   Ms. Emi MacLean   Médecins sans Frontières   New York, NY

OCR for page 199
Scaling Up Treatment for the Global AIDS Pandemic: Challenges and Opportunities 9:20-9:45 Distribution of ARVs: Issues of Security, Logistics, and Quality   Ms. Yasmin Chandani   HIV/AIDS Advisor for DELIVER   John Snow, Inc.   Arlington, VA 9:45-10:10 Large Scale Training for ARV Providers: Observations from the United States   Dr. John McNeil   Chief, Infectious Diseases   Howard University   PI, National Minority AIDS Education and Training Center   Washington, DC 10:10-10:30 General Discussion 10:30-10:50 BREAK 10:50-11:15 Perspectives on Purchasing First and Second Line ARVs   Ms. Lynn Margherio   Executive Vice President   The Clinton Foundation HIV/AIDS Initiative 11:15-11:40 Delivering ARVs: The Economic Consequences of Resistance   Dr. Stefano Bertozzi   Director   Economics and Policy   Center of Research on Health Systems   National Institute of Public Health   Cuernavaca, Mexico 11:40-12:00 General Discussion 12:00-1:00 LUNCH

OCR for page 199
Scaling Up Treatment for the Global AIDS Pandemic: Challenges and Opportunities The Path Forward 1:00-1:25 Assessing Readiness for ARV Program Implementation   Dr. Eric Goosby   Chief Executive Officer   Pangea Global AIDS Foundation   San Francisco, CA 1:25-1:50 Specific Questions for Operations Research in the Scale-up of ARV Treatment Programs in Low-Resource Settings   Dr. Tom Quinn   Professor of Medicine   Johns Hopkins University School of Medicine   Baltimore, MD 1:50-2:15 The Role of Statistical Prediction Methods for Managing ARV Scale-up Programs   Dr. Victor De Gruttola   Professor of Biostatistics   Harvard School of Public Health   Boston, MA 2:15-2:40 Ethical Issues in the Scale-up of ARV Programs in Resource-Poor Settings   Ms. Angela Wasunna   Lawyer/Bioethicist   Associate for International Programs   The Hastings Center   Garrison, NY 2:40-3:05 Discussion 3:05-3:30 BREAK 3:30-3:55 Information Management Considerations in Managing ARV Programs   Mr. Ronaldo Lima   International AIDS Vaccine Initiative   New York, New York

OCR for page 199
Scaling Up Treatment for the Global AIDS Pandemic: Challenges and Opportunities 3:55-4:20 ARV Resistance: Epidemiologic Implications and Public Health Surveillance   Dr. Diane Bennett   World Health Organization   Geneva, Switzerland 4:20-4:45 Monitoring and Evaluation for ARV Programs in Resource-Poor Settings   Dr. Paul DeLay   UNAIDS   Geneva, Switzerland 4:45-5:10 The South African Plan for ARV Scale-up   Dr. Tony Mbewu,   Executive Director   Medical Research Council of South Africa   Capetown, South Africa 5:10-6:00 Discussion and Wrap-up